[1] Rotin D, Kumar S.Physiological functions of the HECT family of ubiquitin ligases[J]. Nature Reviews Molecular Cell Biology, 2009, 10(6):398-409. [2] Pickart CM, Eddins MJ.Ubiquitin:structures, functions, mechanisms[J]. Biochimica Biophysica Acta. Molecular Cell Research, 2004, 1695(3):55-72. [3] Pickart CM.Back to the future with ubiquitin[J]. Cell, 2004, 116(2), 181-190. [4] Jin J, Li X, Gygi SP, et al.Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging[J]. Nature, 2007, 447(7148):1135-1138. [5] Chiu YH, Sun Q, Chen ZJ.E1-L2 activates both ubiquitin and FAT10[J]. Mol Cell, 2007, 27:1014-1023. [6] Pelzer C, Kassner I, Matentzoglu K., et al. UBE1L2, a novel E1 enzyme specific for ubiquitin[J]. Journal of Biological Chemistry, 2007, 282(32):23010-23014. [7] Metzger MB, Hristova VA, Weissman AM.HECT and RING finger families of E3 ubiquitin ligases at a glance[J]. Journal of Cell Science, 2012, 125(Pt 3):531. [8] Zhou MJ, Chen FZ, Chen HC.Ubiquitination involved enzymes and cancer[J]. Medical Oncology, 2014, 31(8):93. [9] Zhao B, Bhuripanyo K, Zhang KY, et al.Orthogonal ubiquitin trans- fer through engineered E1-E2 cascades for protein ubiquitination[J]. Chemistry & Biology, 2012, 19(10):1265-1277. [10] Liu X, Zhao B, et al.Orthogonal ubiquitin transfer identifies ubiqu-itination substrates under differential control by the two ubiquitin activating enzymes[J]. Nat Commun, 2017, 8:14286. [11] Kim SJ, Lee TH, Sang HN, et al.Association of Uba6-Specific-E2(USE1)With Lung Tumorigenesis[J]. Journal of the National Cancer Institute, 2016, 109(3):1-11. [12] Hershko A, Ciechanover A.The ubiquitin system[J]. Annual Review of Biochemistry, 1998, 67:425-479. [13] 王佳悦, 赵博. 泛素化在肿瘤治疗方面的应用及展望[J]. 生命的化学, 2017, 37(6):879-887. [14] 何伟珍, 徐晓东. 泛素-蛋白酶体途径与疾病[J]. 海南医学, 2007, 18(3):141-142. [15] 唐珍, 罗蓉. 泛素-蛋白酶体通路与疾病发生的研究进展[J]. 兰州大学学报:医学版, 2014, 40(3):71-75. [16] Dou QP, Zonder JA.Overview of proteasome inhibitor-based anti-cancer therapies:perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system[J]. Current Cancer Drug Targets, 2014, 14(6):517-536. [17] Sumimoto H, Kawakami Y.Lentiviral vector-mediated RNAi and its use for cancer research[J]. Future Oncol, 2007, 3(6):655-664. [18] Katayama K, Koichiro W, Miyoshi H, et al.RNA interfering approach for clarifying the PPAR pathway using lentiviral vectors expressing short hairpin RNA[J]. FEBS Letters, 2004, 560(3):178-182. [19] Kafri T, Praag HV, Ouyang L, et al.A Packaging cell line for lentivirus vectors[J]. Journal of Virology, 1999, 73(1):576. [20] Naldini L, Blömer U, Gallay P, et al.In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector[J]. Science, 1996, 272(5259):263-267. [21] 张景海, 杨保胜, 颜真, 等. 药学分子生物学[M]. 第4版. 北京:人民卫生出版社, 2013. |